Kornimate/medical-research-clean huggingface dataset:
to assess the utility of the point mini in a clinical take-home study

Conditions: Amputation; Traumatic, Hand; Amputation, Congenital

Summary: the objective of this study is to evaluate the efficacy of the point mini system as compared to the subject's existing prosthetic treatment, which may include a prosthesis, other assistive device, or no device. this study will be a single subject crossover design where one group of 14 children with partial hand deficiencies will be evaluated on several metrics using their existing prosthetic treatment for one month and the point mini system for two months. metrics include: in-clinic functional measures, subjective assessments, bilateral hand use, and prosthesis wear time.


Eligibility criteria:
inclusion criteria: * partial hand loss with at least index and/or middle finger loss at the metacarpophalangeal (mcp) level * intact thumb with full range of motion * fluent in english * age between 5 and 15 years exclusion criteria: * patients with a residual limb that is unhealed from the amputation surgery * unhealed wounds * significant cognitive deficits as determined upon clinical evaluation * significant neurological deficits as determined upon clinical evaluation * significant physical deficits of the residual limb impacting full participation in the study as determined upon clinical evaluation * uncontrolled pain or phantom pain impacting full participation in the study as determined upon clinical evaluation * serious uncontrolled medical problems as judged by the project therapist
a study of ak112 in patients with unresectable hepatocellular carcinoma (hcc)

Conditions: Hepatocellular Carcinoma

Summary: phase ii open label, multicenter study to evaluate the efficacy and safety of ak112 (pd-1/vegf bispecific) in patients with unresectable hepatocellular carcinoma (hcc).


Eligibility criteria:
inclusion criteria: * be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures). * 18 to 75 years old. * eastern cooperative oncology group (ecog) performance status of 0 or 1. * have a life expectancy of at least 3 months. * bclc stage b or c, not amenable to curative surgery. * hepatocellular carcinoma confirmed by histology/cytology. cirrhosis meets the clinical diagnostic criteria for hepatocellular carcinoma of the american association for the diagnosis of liver diseases (aasld). * at least one measurable untreated lesion. * child-pugh class a. * has adequate organ function. * all female and male subjects of reproductive potential must agree to use an effective method of contraception, as determined by the investigator, during and for 120 days after the last dose of study treatment. exclusion criteria: * with fibrous lamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma components in tumor tissues. * history of malignancy other than hcc within 5 years, except that basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. * have a history of hepatic encephalopathy or have a history of liver transplantation. * with clinical symptoms requires drainage of pleural effusion, ascites or pericardial effusion. * central nervous system (cns) metastasis or meningeal metastasis. * prior immunotherapy with an anti-pd-1, anti-pd-l1, or anti-ctla-4 antibody (or any other antibody or drug specifically targeting t-cell costimulation or checkpoint pathways). * prior systemic bevacizumab and its analogues treatment. * severe bleeding tendency or coagulation dysfunction; occurred arteriovenous thromboembolic events or bleeding events due to esophageal and/or gastric varices within 6 months before the first administration. * known presence or history of required hormone treatment interstitial lung disease or non-infectious pneumonitis. * has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). replacement therapy (e.g., thyroxine, insulin or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. * has undergone major surgery within 30 days prior to the first dose of study treatment. * history of myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or surgery within 12 months. * has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
meditation-based stress reduction in rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to determine whether a mindfulness meditation-based stress reduction program is useful in relieving symptoms associated with rheumatoid arthritis (ra).


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of ra, with doctor's letter or doctors' bill with icd code 714; * 18 years of age or older; * able to read and write english; * able to attend 15 course sessions and questionnaire sessions at kernan hospital in baltimore; * willing to practice skills for 45 minutes to 1 hour per day, 6 days a week; * stable on rheumatoid medications for at least one month. exclusion criteria: * major psychiatric illness (bipolar disorder, multiple personality disorder, etc.); * active alcoholism or drug dependency; * scheduled for major surgery during the study period; * enrolled in randomized clinical trial for rheumatoid arthritis during the study period; * planning to move out of the area in the next 12 months; * unwilling to be enrolled in a control group; * use of assistive device other than a cane; * serious health condition(s) that the investigator determines would make it difficult to complete the 6 month study; * diagnosis of fibromyalgia.

Keywords: rheumatoid arthritis stress reduction meditation mindfulness mbsr mindfulness-based stress reduction mind-body skills
expectation, motivation and experience of hiv-patients regarding participation to an hiv cure-related clinical trial

Conditions: HIV Seropositivity

Summary: following the anrs-apsec survey, amep-ehva t02 is a longitudinal social science study that will explore the experience of people living with hiv (plwh) who were offered to participate in the european randomized phase ii placebo-controlled trial of vedolizumab with or without therapeutic hiv mva vaccine including antiretroviral treatment interruption (ehva t02/anrs vri07).

moving towards the discovery of an hiv cure is of major public health interest, not only for people living with hiv (plwh) who currently must take lifelong antiretroviral treatment (art), with its associated side effects and comorbidities, but also for the community as a whole. an hiv cure will end the virus transmission, lead to global care-related savings and decrease in hiv-related stigma. the present longitudinal social science study concerns the experience of plwh who were offered to participate in the european randomized phase ii placebo-controlled trial of vedolizumab with or without therapeutic hiv mva vaccine including art treatment interruption (ehva t02/anrs vri07). the objectives are to document: 1. the evolution over time of expectations and motivations related to participation in the trial, 2. anticipation and understanding of risks and benefits related to participation, 3. evolution over time of participation experience and of satisfaction with the information delivered, 4. experience and perception of the ati period and its impact on preventive behaviours and sexual quality of life, 5. motivations and experience related to refusal of participation, or if any, related to non-inclusion because of negative screening results. this international multicentre longitudinal study will be nested within the ehva t02/anrs vri07 trial, and will comprise two components. a quantitative component designed to answer to the four first objectives, and a qualitative one that will retrospectively deepen the trial participation experience and will also document the motivation for participation refusal and the experience of participants not included because of negative screening results (objective 5). the quantitative survey will be conducted within participating centres that estimate to include at least 5 participants, and the qualitative one only in france for feasibility purpose.

Eligibility criteria:
inclusion criteria: * people living with hiv * who were offered to participate in ehva t02 clinical trial

Keywords: hiv cure-related clinical trials participants' expectations and experiences
effects of low intensity blood flow restriction on clinical outcomes in women with knee osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: objective is to compare the effects of routine physical therapy with and without low intensity blood flow restriction on pain and quadriceps muscle strength in women with knee osteoarthritis. a single blinded randomized controlled trial conducted at department of physiotherapy, university of lahore teaching hospital, defense road, lahore. total 60 participants were randomly assigned in to two groups, with 30 in each group the intervention group received routine physiotherapy program combined with low intensity blood flow restriction technique (li-bfr. while control group were treated with only routine physiotherapy. dynamometer was used to assess the knee extensor strength while knee injury and osteoarthritis outcome score was used to record any exacerbation in pain and effects of bfr on activities of daily living. training load determined 20% of 1rm. data analysis had done on spss version 23.

nonparametric test friedman test was for comparison within the groups and mann whitney u test was used for comparison between groups. randomization had done through the sealed envelope method. after allocation subjects had received their treatment protocals.

Eligibility criteria:
inclusion criteria: * diagnosed patients of grade ii knee osteoarthritis * patient's age 45-65 exclusion criteria: * bilateral knee replacement * lower limb surgery in the last six months * diagnosis of inflammatory joint or muscle disease * chest pain during exercise or at rest; or need for supplemental oxygen * pregnancy * any systemic disease
reducing mental health in informal caregivers

Conditions: Mental Health Issue; Grief; Burden, Caregiver

Summary: the overarching goal of this project is to evaluate if evidence-based interventions can reduce pdg, burden, and stress in informal caregivers of individuals with dementia

aim 1: examine the effects of two individual evidence-based therapies for informal caregivers of dementia patients. aim 2: examine the effects of a modified evidence-based group therapy for informal caregivers of dementia patients.

Eligibility criteria:
inclusion criteria: * participants must be informal caregivers (e.g., spouse; child; close friend) of individuals with dementia * informal caregivers can be family members or close friends * adults (18 to 89 years old) who read, write, and speak in english * mental health diagnosis (e.g., generalized anxiety disorder; major depressive disorder exclusion criteria: * formal caregivers (who are being paid to take care of the patient) * any informal caregivers with cognitive impairment is identified during the assessment.
treatment for patients suffering from anemia due to chemotherapy

Conditions: Breast Cancer; Anemia

Summary: the purpose of this study is to validate a patient satisfaction questionnaire for anemia treatment (psq-at) in female breast cancer patients treated with darbepoetin alfa or recombinant human erythropoietin (rhuepo) for anemia due to chemotherapy.


Eligibility criteria:
inclusion criteria: - female subjects receiving multi-cycle chemotherapy - anemia due to chemotherapy (hgb less than or equal to 11.0 g/dl) - expected to receive greater than or equal to 8 additional weeks of chemotherapy as part of their planned treatment - karnofsky performance scale (kps) greater than or equal to 50% - adequate renal function - adequate liver function exclusion criteria: - iron deficiency - unstable cardiac disease - known positive test for human immunodeficiency virus (hiv) infection

Keywords: breast cancer darbepoetin alfa amgen
personalized chimeric antigen receptor t cell immunotherapy for patients with recurrent malignant gliomas

Conditions: Glioma; Malignant Glioma of Brain; Recurrence Tumor

Summary: a pilot study to determine the safety and efficacy of chimeric antigen receptor t cell (autologous t cells transduced with a lentiviral vector expressing chimeric antigen receptor with or without anti-pdl1 antibody) personalized immunotherapy for patients with recurrent malignant gliomas based on the expression of tumor specific/associated antigens (egfrviii, il13rα2, her-2, epha2, cd133, gd2).


Eligibility criteria:
inclusion criteria: * voluntary informed consent for entry of trial; * age greater than 18 years, and less than 70 years; * pathologically confirmed recurrent malignant gliomas; * tumor cells from resected tissue must be available for antigen testing (egfrviii, il13rα2, her-2, cd133, epha2, gd2) and at least one of the targets should be tested positively by immunohistochemistry study; * if the patient is on dexamethasone, the anticipated dose must be 4 mg/day or less for at least 5 days prior to apheresis. * patients must have a karnofsky performance status of greater than or equal to 70. * life expectancy greater than 3 months; * participants with adequate organ function as measured by: 1. white blood count greater than or equal to 2500/mm\^3; platelets greater than or equal to 100,000/mm\^3, hemoglobin greater than or equal to 10.0 g/dl; without transfusion or growth factor support 2. aspartate transaminase (ast), alanine transaminase (alt), gamma glutamyl transpeptidase (ggt), lactic acid dehydrogenase (ldh), alkaline phosphatase within 2.5 x upper normal limit, and total bilirubin less than or equal to 2.0 mg/dl 3. serum creatinine less than or equal to 1.5 x upper limit of normal 4. coagulation tests prothrombin time (pt) and partial thromboplastin time (ptt) have to be within normal limits, unless the patient has been therapeutically anti-coagulated for previous venous thrombosis. exclusion criteria: * female subjects of reproductive potential who are pregnant or lactating; * previous treatment with any gene therapy products or other form immunotherapy; * uncontrolled active infection. * active or latent chronic hepatitis b \[detectable hepatitis b surface antigen (hbsag)\] or active hepatitis c (positive serology \[hepatitis c virus ab\]) infection. * hiv infection; * history of allergy or hypersensitivity to study product excipients (human serum albumin, dimethyl sulfoxide, and dextran 40); * currently enrolled in other clinical trials;
liposomal bupivacaine and transoral robotic surgery

Conditions: Oropharyngeal Cancer; Dysphagia, Oropharyngeal; Post Operative Pain; Transoral Robotic Surgery

Summary: this study is for patients with oropharyngeal squamous cell carcinoma. we want to learn more about how we can optimize pain control in patients who undergo transoral robotic surgery (tors) for oropharyngeal squamous cell carcinoma. our goal is to determine if a local anesthetic called exparel® (liposomal bupivacaine) impacts postsurgical pain and swallow function in patients with oropharyngeal squamous cell carcinoma undergoing tors. exparel® is an fda-approved anesthetic drug that provides long-lasting and precise pain relief when injected into the surgical wound. our study team wants to determine if injecting exparel® into the surgical wound will provide better pain relief and swallow function when compared to patients who do not undergo postoperative exparel® injection. both options for postoperative pain control are considered standard of care for patients undergoing tors.


Eligibility criteria:
inclusion criteria: * adult patients, greater than or equal to 18 years of age; patients of all genders; patients undergoing transoral robotic surgery; patient who are able and willing to give consent exclusion criteria: * patients with an allergy to bupivacaine or other amide anesthetics; patients with a carnitine deficiency

Keywords: oropharyngeal cancer squamous cell carcinoma postoperative pain transoral robotic surgery
assessment of kidney function for drug dosage adjustments in critically ill patients

Conditions: ICU Patients

Summary: the aim of the study is to determine if colistin dosage adjustment using 4hr crcl contribute to better clinical outcomes compared with drug dosage adjustment using egfr in critical ill patients. in control group, colistin maintenance dosage will be decided using serum creatinine based egfr (in ml/min). in study group, colistin maintenance dosage will be decided using 4hr crcl.

1. screening periods (from 'informed consents' to 'randomization') * check of inclusion/exclusion criteria ② measurement of 4hr crcl \& egfr in ml/min * calculation of maintenance dose ③ baseline characteristics \& laboratory findings ④ randomization 2. colistin dosage loading dose : 5 x body weight (not exceeding 300mg) maintenance dose (after 12 hours from loading dose) : 2.5 x (\[1.5 x gfr\] + 30) (divided doses every 12hours), gfr in ml/min during the study period, daily morning serm creatinine levels are measured. whenever serum creatinine concentration changes by more than 10% compared with baseline, 4hr crcl will be mearued. at the every time of 4hr crcl measurements, colistin dose wil be modified according to new gfr values (4hr crcl in study group, egfr in control group) 3. blood sampling for colistin trough level measurement peripheral blood will be sampled twice between 72 hrs and 144 hours after loading dose, just before colistin infusion. the samples were collected in heparined tubes and centrifuged at 4 °c within 1 hr of collection. the resulting plasma was stored at - 70°c . and two values will be averaged out. 4. end of randomization (7 days after colistin initiation) ① nephrotoxicity ② treatment outcome microbiological outcome: eradication / no eradication clinical outcome: complete response / partial response / treatment failure

Eligibility criteria:
inclusion criteria: 1. patients aged over 18 2. patients in intensive care unit received colistin for the microbiologically documented cases associated with carbapenem-resistant gram negative bacilli. exclusion criteria: 1. patients who received colistin empirically. 2. patients who received renal replacement therapy due to acute kidney injury or end-stage renal disease 3. patients whose urine output was less than 0.5cc/kg/hr for 6 hrs 4. patients who underwent hematopoietic stem cell transplantation 5. patients who disagree with this study.

Keywords: drug dosing, egfr, ccr
sevoflurane/dexmedetomidine vs. isoflurane for pediatric emergence delirium

Conditions: Delirium on Emergence

Summary: the purpose of this study is to measure the incidences of pediatric emergence delirium between the group receiving isoflurane and the group receiving sevoflurane plus intravenous push dexmedetomidine.


Eligibility criteria:
inclusion criteria: * pediatric patients aged 2-7 years. * surgeries include ent cases (i.e., tonsillectomy/adenoidectomy), ophthalmology cases (i.e., strabismus), and urology cases. * can be outpatient or general care inpatient procedures. * all cases must include an iv and an endotracheal tube (ett). exclusion criteria: * severe developmental/cognitive delay (unable to make eye contact, nonverbal, or inability to interact with providers for paed scale assessment requirements) * tiva cases. * no piv in place during the case, planned picu admission postoperatively. * previous history of severe emergence delirium documented by a provider (via interventions or explicitly stated).
implementation of group problem management plus (pm+) in adult syrian refugees in turkey: rct (strengths)

Conditions: Anxiety; Depression; Posttraumatic Stress Disorder; Psychological Distress

Summary: to implement group problem management plus (pm+) in syrian refugees with this rct to evaluate feasibility, acceptability, effectiveness and cost-effectiveness of the culturally adapted group pm+ intervention for adult syrian refugees in turkey.

the strengths (syrian refugees mental health care systems) study is a 5-year study that started in january 2017 with funding from the european commission horizon 2020 scheme. turkey is one of the eight sites in strengths project that this study will be conducted. the main aim of strengths in turkey is to evaluate the feasibility, acceptability, effectiveness and cost-effectiveness of the culturally adapted psychological intervention group problem management plus (pm+) intervention for adult syrian refugees in turkey. study participants (n=380) will consist of adult syrian refugees (18 years and older) in turkey with self-reported functional impairment (whodas 2.0 \>16) and elevated psychological distress (k10 \>15.9). participants will be randomly allocated either to the treatment group who will receive five sessions of pm+ or to the enhanced care-as-usual (e-cau) group. participants in the comparison group will receive e-cau only. the primary outcome will be the decrease in psychological distress from baseline to three-month post-intervention assessment, measured through the hopkins symptoms checklist (hscl-25).

Eligibility criteria:
inclusion criteria: * adults of 18 years or above * syrian under temporary protection status * arabic-speaking * elevated levels of psychological distress (k10 \>15) and reduced psychosocial functioning (whodas 2.0 \>16) exclusion criteria: * acute medical conditions * imminent suicide risk or expressed acute needs/protection risks (e.g., a young woman who expresses that she is at acute risk of being assaulted or killed) * severe mental disorder (psychotic disorders, substance-dependence) * severe cognitive impairment (e.g., severe intellectual disability or dementia)

Keywords: refugees mental health
longitudinal surveillance of rectal colonization and transmission by resistant bacteria in acutely decompensated cirrhosis

Conditions: Cirrhosis, Liver; Rectal Colonization; Multidrug Resistance Organisms

Summary: antimicrobial resistance has emerged as a global threat, and multidrug resistance organisms (mdros) form one of the foremost challenges in the setting of decompensated cirrhosis. in a worldwide study, a high prevalence (34%) of infection with mdr bacteria in patients with cirrhosis and associated with higher in-hospital mortality. previous study indicated that the pattern of colonized bacteria in heterogeneous and the colonization by mdros is associated with increased risk of infection. effort should be made to reduce the spread of mdr bacteria and improvement in prognosis in patents with cirrhosis. currently, strategies suggested to prevent the spread of mdros in cirrhosis, including rapid microbiological tests, new first-line antibiotic schedules, infection control practices and epidemiological surveillance. thus, for the aims of this cohort study are as following. firstly, to characterize the burden, dynamics and risk factors associated with rectal colonization by mdros in patients with cirrhosis. secondly, to completely characterize the risk that asymptomatic carriers of mdros, both to other patients and to themselves via collecting detailed longitudinal sampling and high-resolution typing. lastly, to generate evidence for future policymaking for individualized antimicrobial decision rather than umbrella guidelines since the variance in the bacteriological profiles in different settings.


Eligibility criteria:
inclusion criteria: 1. age\>18 years old; 2. inpatients; 3. cirrhosis patients with acute decompensation; exclusion criteria: 1. patients decline any swab type; 2. patients had liver resection or other organ transplantation; 3. patients who had participated in, or are planning to participate in other clinical trial within the 3 months prior to enrollment; 4. hospital stays \<48 hours; 5. not suitable to participate in this study judging by researchers;